/

INSM

Insmed IncorporatedPre-market

98.56−2.04 −2.03%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

98.82

Prev close

100.60

Day range

98.33100.31

52-week range

90.39212.75

Volume

1.70M0.66×

Mkt cap

21.52B

P/E ttm

—

Fwd P/E

125.17

EPS ttm

-4.18

Div yield

0.00%

Earnings

Oct 29, 2026

From 52w high

−53.67%

Price Chart

Yahoo Finance · delayed

INSMOct 12, 2026O 98.82H 100.31L 98.33C 98.56−2.04 (−2.03%)Vol 1.70M

SMA 50119.64
SMA 200130.67

1Y change −39.28% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INSM Insmed Incorporated · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.08%
1 month: −23.84%
3 months: −9.69%
6 months: −34.79%
Year to date: −43.37%
1 year: −39.28%

Valuation & ownership

Market cap: 21.52B
Enterprise value: 21.10B
P/E (ttm): —
Forward P/E: 125.17
PEG ratio: 1.09
Price / book: 28.40
Price / sales (ttm): 18.92
EV / EBITDA: -26.55
EPS (ttm): -4.18
EPS (forward): 0.7874
Beta (5y monthly): 0.82
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 218.38M
Float: 216.92M
Short % of float: 7.12%
Short ratio (days): 6.46
Held by insiders: 0.51%
Held by institutions: 105.06%
Avg volume (3m): 2.57M
50-day average: 119.64
200-day average: 130.67
52-week change: −39.28%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 28.0
vs 50-day SMA: −17.62%
vs 200-day SMA: −24.58%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.95%
Realised vol (20d, ann.): 41.4%
From 52-week high: −53.67%
From 52-week low: +9.04%

ANR

Analyst Consensus

22 analysts

Consensus

Strong buy

1.29 on a 1 (strong buy) – 5 (sell) scale

Mean target

198.45

+101.35% implied

Low 169.00Median 196.50High 243.00

Recommendation trend

Now23 / 1 / 0
1m ago24 / 0 /

DES

About Insmed Incorporated

Yahoo Finance profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 1,664
Headquarters: Bridgewater, NJ, United States

SEAS

Seasonality · INSM

2007–2026 · monthly returns

Strongest month Feb +12.25%Weakest month Aug −5.08%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-9.9	-4.8	9.5	-16.6	-21.6	-0.3	-7.5	23.5	-6.3	-13.6			−43.4%
2025	10.9	6.5	-6.5	-5.6	-3.2	44.3	6.6	26.9	5.8	31.7	9.6	-16.2	+152.1%
2024	-10.3	-0.3	-2.1	-8.9	122.7	21.7	8.6	5.1	-4.5	-7.8	11.7	-8.1	+122.8%
2023	7.8	-5.3	-16.3	14.4	-2.4	10.9	4.7	-0.9	15.3	-0.8	-0.2	23.9	+55.1%
2022	-16.7	5.4	-1.7	-6.5	-14.3	4.8	12.2	11.3	-12.5	-19.6	6.8	8.1	−26.7%
2021	12.9	-4.8	-4.8	-1.0	-27.1	15.7	-13.6	14.0	-1.8	9.5	-8.7	-1.0	−18.2%
2020	-14.0	21.2	-35.6	43.5	5.6	13.4	-5.2	7.9	14.0	2.5	18.4	-14.7	+39.4%
2019	85.3	22.0	-2.0	4.7	-20.5	5.7	-14.3	-25.1	7.3	5.4	24.0	3.6	+82.0%
2018	-18.4	-4.8	-7.0	8.0	14.5	-15.1	5.2	-19.9	1.5	-27.8	22.7	-26.7	−57.9%
2017	11.6	7.9	9.9	5.4	-16.4	11.3	-5.8	-23.2	151.3	-13.5	15.5	-0.0	+135.7%
2016	-27.3	-7.3	3.6	-4.1	-2.9	-16.4	16.1	13.1	12.1	-10.6	5.2	-3.1	−27.1%
2015	-0.1	19.9	12.2	-3.7	9.5	11.3	11.0	-9.8	-24.0	6.8	-17.8	11.3	+17.3%
2014	20.1	-2.0	-4.8	-26.8	-5.7	52.1	-14.5	-18.5	-6.3	8.7	-0.6	9.6	−9.0%
2013	-12.6	5.3	21.6	22.3	46.5	-10.9	-7.5	37.5	2.6	-8.8	13.8	4.9	+154.1%
2012	58.0	-11.6	-14.8	-20.4	-2.4	15.6	4.3	-4.7	40.4	40.4	12.1	-6.6	+119.3%
2011	-6.3	-6.8	22.7	29.0	23.1	11.8	-4.2	-58.7	6.9	-30.5	-8.8	-5.3	−51.6%
2010	7.8	25.3	12.5	-8.5	-24.3	-17.3	7.5	1.4	-1.4	1.4	0.0	-13.7	−18.2%
2009	-6.4	109.1	8.7	33.0	26.3	-40.5	-1.0	-11.1	-6.8	-14.6	10.0	0.0	+63.8%
2008	-10.8	5.4	-12.8	4.4	-15.5	-33.3	72.5	-30.4	6.2	-27.5	67.6	-24.2	−43.4%
2007	9.1	47.9	-33.8	10.6	-26.0	5.2	-13.6	-11.4	11.3	24.6	3.5	-6.7	−5.7%

INSD

Insider Activity · INSM

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

391K shares

Sells, 6 months

495.3K shares

Net shares

−104.3K

Net change in insider shares

−8.60%

Date	Insider	Transaction	Shares	Value
Sep 8, 2026	Brennan David RDirector	Sale at price 124.00 per share.	25K	$3.10M
Aug 16, 2026	Sharoky Melvin ADirector	Sale at price 127.53 per share.	5K	$637.65K
Aug 9, 2026	Adsett RogerChief Operating Officer	Sale at price 133.27 per share.	239.8K	$31.96M
Aug 9, 2026	Adsett RogerChief Operating Officer	Conversion of Exercise of derivative security at price 13.67 - 30.46 per share.	239.8K	$4.91M
Aug 5, 2026	Flammer MartinaOfficer	Sale at price 127.00 - 129.40 per share.	27.2K	$3.49M
Aug 5, 2026	Flammer MartinaOfficer	Conversion of Exercise of derivative security at price 18.95 - 25.83 per share.	27.2K	$576.13K
Jul 22, 2026	Lewis William HChief Executive Officer	Sale at price 105.62 - 106.43 per share.	10.7K	$1.13M
Jul 22, 2026	Lewis William HChief Executive Officer	Conversion of Exercise of derivative security at price 17.16 - 30.46 per share.	10.7K	$266.87K
Jul 8, 2026	Lewis William HChief Executive Officer	Sale at price 116.55 - 118.52 per share.	10.7K	$1.26M
Jul 8, 2026	Lewis William HChief Executive Officer	Conversion of Exercise of derivative security at price 17.16 - 30.46 per share.	10.7K	$266.84K
Jul 5, 2026	Flammer MartinaOfficer	Sale at price 109.02 - 110.60 per share.	12.3K	$1.35M
Jul 5, 2026	Flammer MartinaOfficer	Conversion of Exercise of derivative security at price 19.74 - 29.13 per share.	12.3K	$317.44K
Jun 24, 2026	Lewis William HChief Executive Officer	Sale at price 102.34 - 106.27 per share.	21.4K	$2.21M
Jun 24, 2026	Lewis William HChief Executive Officer	Conversion of Exercise of derivative security at price 17.16 - 30.46 per share.	21.4K	$533.68K
Jun 22, 2026	Butera SamueleOfficer	Stock Award(Grant) at price 0.00 per share.	7.3K	—
Jun 21, 2026	Smith Michael AlexanderOfficer	Sale at price 95.82 per share.	1.8K	$173.05K
Jun 7, 2026	Lewis William HChief Executive Officer	Sale at price 94.03 per share.	6.5K	$612.61K
Jun 4, 2026	Flammer MartinaOfficer	Sale at price 102.27 - 103.78 per share.	4.4K	$455.25K
Jun 2, 2026	Bonstein Sara MChief Financial Officer	Sale at price 102.27 per share.	2.4K	$245.86K
Jun 2, 2026	Adsett RogerChief Operating Officer	Sale at price 102.27 per share.	2.4K	$242.38K

CONG

Congress Trades · INSM

House reports since 2025

Members

0 last bought

Buys

~$8.0K

Sells

~$48.0K

Net

−$40.0K

est. bought − sold

Latest

Jun 10, 26

Josh Gottheimer

Members who traded it

Member	Buys	Sells	Est. net	Last move
Josh Gottheimer NJ05	1	2	−$8.0K	Trimmed Jun 10, 26
Gilbert Cisneros CA31		4	−$32.0K	Sold Oct 3, 25

Bought and sold by quarter (est.)

House members' INSM trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Jun 10, 26	Josh Gottheimer NJ05	Joint	Sell (part)	$1,001 - $15,000	Jul 7, 26 (27d)	PDF
Oct 3, 25	Gilbert Cisneros CA31	Self	Sell	$1,001 - $15,000	Nov 18, 25 (46d)	PDF
Sep 22, 25	Gilbert Cisneros CA31	Self	Sell (part)	$1,001 - $15,000	Oct 10, 25 (18d)	PDF
Aug 8, 25	Gilbert Cisneros CA31	Self	Sell (part)	$1,001 - $15,000	Sep 12, 25 (35d)	PDF
Jul 7, 25	Gilbert Cisneros CA31	Self	Sell (part)	$1,001 - $15,000	Aug 14, 25 (38d)	PDF
Jun 16, 25	Josh Gottheimer NJ05	Joint	Buy	$1,001 - $15,000	Jul 16, 25 (30d)	PDF
Apr 9, 25	Josh Gottheimer NJ05	Joint	Sell (part)	$1,001 - $15,000	May 14, 25 (35d)	PDF

From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

INSM

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INSM

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Insmed Incorporated

Seasonality · INSM

Insider Activity · INSM

Congress Trades · INSM

Members who traded it

Bought and sold by quarter (est.)

Congress Trades · INSM

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · INSM

Seasonality · INSM

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Insmed Incorporated

Financial Snapshot

Earnings & Dividends

News